carcassi hla pharmacogenomics · 2018-04-01 · hla and pharmacogenomics the abacavir story...

20
HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Upload: others

Post on 14-Mar-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

HLA and Pharmacogenomics The Abacavir Story

EFI-ASHI-APHIA Summer School 2013 Stintino

16 – 18 September 2013

Carlo Carcassi

Page 2: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

2

Rx + =

Rx + =

????

Rx + =

Page 3: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

3

Rx + =

Rx + =

Differences in genetic constitution

Rx + =

Page 4: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

4

PHARMACOGENETICS

The study of genetically controlled variations in drug

response

Page 5: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi
Page 6: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

6

GENETIC POLYMORPHISMS

Pharmacokinetic Pharmacodynamic

• Transporters • Plasma protein binding • Metabolism

• Receptors • Ion channels • Enzymes • Immune molecules

Page 7: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi
Page 8: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Abacavir is a nucleoside reverse transcriptase inhibitor used in

conjunction with other antiretroviral agents in the treatment of HIV

infection.

Page 9: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Abacavir is generally well tolerated but can cause hypersensitivity in 5% to 8% of patients during the first 6

weeks of treatment

Page 10: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Hypersensitivity to abacavir is immunologically

mediated, driven by conventional MHC-I

antigen presentation and activation of HLA-

B*5701. Activation of HLA-B*5701 restricted

CD8+ T cells results in the secretion of the

inflammatory mediators TNF-alpha and IFN-

gamma and induces the delayed-type

hypersensitivity reaction

Page 11: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Reeves et al. HIV Medicine 2006

Page 12: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi
Page 13: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Clin Infect Dis. (2008) 46 (7): 1111-1118.

Page 14: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Clin Infect Dis. (2008) 46 (7): 1111-1118.

Page 15: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

INDIA 5-20%

JAPAN 0%

CHINA 0% (NB 2.5% N.E.

provinces)

UK ~8%

MIDDLE EAST 1-2% (NB 5-7% Ashkenazi Jews)

AUSTRALIA ~8%

US Caucasian

~8% US Asian

~1%

US African-

American ~2.5%

W. EUROPE 5-7%

THAILAND 4-10%*

*THAILAND B*57 carriage: Urban Bangkok 3.6%

Thai Dai Lue (NE Thai) ~11% Southern Thai Muslim 3%

MEDITERRANEAN 1-2%

S. AMERICAN Caucasian

5-7%

US Hispanic

~2%

Subsaharan AFRICA

<1%

HLA-B*5701 carriage frequency

Nolan et al, J HIV Ther 2003; 8(2):36-41

Page 16: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

To recommend screening for HLA-

B*5701 in European populations or of

European origin but not in some Asian

or African populations could be

problematic?

Page 17: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Ancestry and Disease in the Age of Genomic Medicine N Engl J Med 363;16 October 14, 2010

Page 18: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

N Engl J Med 363;16 October 14, 2010

Page 19: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Webuye

Kinyawa

N Engl J Med 363;16 October 14, 2010

Page 20: Carcassi HLA Pharmacogenomics · 2018-04-01 · HLA and Pharmacogenomics The Abacavir Story EFI-ASHI-APHIA Summer School 2013 Stintino 16 – 18 September 2013 Carlo Carcassi

Louvre National Gallery

Virgin of the Rocks ( 1495 - 1508 )

Virgin of the Rocks (Madonna and child, San Giovannino and angel) is an oil painting on a panel of 189,5 x 120 cm, executed between

1495 and 1508 by Leonardo da Vinci.